Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf197 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Jing Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To assess CIN3+ risk in a Chinese cohort of outpatients undergoing contesting screening and to evaluate the portability of the American Society for Colposcopy and Cervical Pathology (ASCCP) risk-based management, which was primarily developed using data from the Kaiser Permanente of Northern California (KPNC) cohort.
Methods
Females aged 25-65 years who were screened with cytology and high-risk human papillomavirus (hrHPV) co-testing between 2011 and 2020 at Wuhan Union Hospital (WHUH) were retrospectively studied. The risks of immediate and 3-year CIN3+ were estimated via prevalence-incidence mixture models. Portability was evaluated via the ratio of the observation risk in the WHUH cohort to the expected risk in the KPNC cohort (O/E) and its 95% CI.
Results
A total of 96 318 females were included, and 16.83% of the women tested hrHPV-positive at initial screening, who had a CIN3+ immediate risk of 14.14%. The CIN3+ immediate risk varied between subgroups of positive HPV16 (34.09%), HPV18 (13.38%), other HPV types (6.71%), and negative hrHPV (0.12%). Compared to the KPNC cohort, our cohort exhibited a significantly higher CIN3+ immediate risk (1.42% vs 0.46%; O/E, 3.09; 95% CI, 2.92-3.26) and disproportionately increased cancer immediate risks in most subgroups requiring immediate colposcopy or treatment, as well as higher 3-year CIN3+ risks in women with hrHPV-negative ASC-US/NILM. Yet, the action threshold suggested by ASCCP, a CIN3+ immediate risk of 4%, showed good portability to our cohort.
Conclusions
Despite the higher risks in our cohort, the ASCCP clinical action threshold remains portable. For women with minimal abnormalities or normal results, shortened follow-up intervals should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Gynecology, Maternal and Child Health Hospital of Hubei Province, Wuhan 430022, China.
- Department of Gynecology, The Second Affiliated Hospital of Zhengzhou University, Henan Provincial Clinical Research Center for Gynecologic Oncology, Zhengzhou 450014, China.
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
ORCID-Profile: Jing Cai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhao, J., Li, W., Wang, Z., Liu, W., Sun, S., Wu, L., Du, S., Li, G., Pan, Z., Chen, D., Yang, P., Wang, W., Cai, L., Huang, B., & Cai, J. (2025). Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening. The Oncologist. https://doi.org/10.1093/oncolo/oyaf197
Vancouver
Zhao J, Li W, Wang Z, Liu W, Sun S, Wu L, et al. Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening. The Oncologist. 2025. doi:10.1093/oncolo/oyaf197
BibTeX
@article{Zhao2025,
author = {Zhao, Jing and Li, Wenhan and Wang, Zehua and Liu, Weichao and Sun, Si and Wu, Liying and Du, Shi and Li, Guoqing and Pan, Zhongya and Chen, Dingyu and Yang, Pinglan and Wang, Wuliang and Cai, Liqiong and Huang, Bangxing and Cai, Jing},
title = {Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf197}
}
EUVIMED